McPherson et al., 1990 - Google Patents

Radiolabeling of proteins with radioisotopes of copper using p‐carboxyalkylphenylglyoxal bis‐(4N‐methylthiosemicarbazone)(TSC) bifunctional chelates

McPherson et al., 1990

Document ID
9750893745439900588
Author
McPherson D
Umbricht G
Knapp Jr F
Publication year
Publication venue
Journal of Labelled Compounds and Radiopharmaceuticals

External Links

Snippet

A series of p‐carboxyalkylphenylglyoxal and p‐carboxyalkyl‐1, 2‐diketo‐bis‐(N4‐ methylthiosemicarbazone) bifunctional ligands (TSC) have been prepared and evaluated for use in binding radioisotopes of copper to antibodies. We have developed an improved …
Continue reading at analyticalsciencejournals.onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
US5639879A (en) Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging
US5435990A (en) Macrocyclic congugates and their use as diagnostic and therapeutic agents
Jones-Wilson et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes
US5652361A (en) Macrocyclic ligands and complexes
US5756065A (en) Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
Roesch et al. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry
US5183653A (en) Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
AU2008203856B8 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
Boswell et al. Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling
Navarro et al. Prosthetic groups for radioiodination and astatination of peptides and proteins: A comparative study of five potential bioorthogonal labeling strategies
Berdal et al. Investigation on the reactivity of nucleophilic radiohalogens with arylboronic acids in water: access to an efficient single-step method for the radioiodination and astatination of antibodies
Choudhary et al. Octadentate oxine-armed bispidine ligand for radiopharmaceutical chemistry
JPH05239046A (en) Rhenium and technetium complex containing hypoxia locality residue
McPherson et al. Radiolabeling of proteins with radioisotopes of copper using p‐carboxyalkylphenylglyoxal bis‐(4N‐methylthiosemicarbazone)(TSC) bifunctional chelates
IL92860A (en) Process for preparing isothiocyanato functionalized metal complexes with rhodium
Chu et al. Synthesis and biodistribution of 99mTc-carbonyltechnetium-labeled fatty acids
Wharton et al. [213Bi] Bi3+/[111In] In3+-neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma─ Structural, Radiochemical, and Biological Evaluation
TWI381852B (en) Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents
Saied et al. Preparation and biodistribution of 1-((2-methoxyphenyl) piperazine) ferrocenecarboxamide labeled with technetium-99m as a potential brain receptor imaging agent
Jain et al. Development of 68 Ga labeled human serum albumin for blood pool imaging: a comparison between two ligands
Goswami et al. Rhodium-105 tetrathioether complexes: radiochemistry and initial biological evaluation
US6613304B2 (en) Radiometal complexes of 2-pyrrolylthiones and their use as radiopharmaceuticals for imaging and therapy
Gano et al. Radiolanthanide complexes with tetraazamacrocycles bearing methylphosphonate pendant arms as bone seeking agents
Chakraborty et al. Syntheses and evaluation of 68Ga‐and 153Sm‐labeled DOTA‐conjugated bisphosphonate ligand for potential use in detection of skeletal metastases and management of pain arising from skeletal metastases
Sogbein et al. Aqueous fluoride and the preparation of [99mTc (CO) 3 (OH2) 3]+ and 99mTc− carborane complexes